Literature DB >> 9108089

Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology.

V Schumacher1, S Schneider, A Figge, G Wildhardt, D Harms, D Schmidt, A Weirich, R Ludwig, B Royer-Pokora.   

Abstract

The WT1 gene, located on chromosome 11p13, is mutated in a low number of Wilms tumors (WTs). Germ-line mutations in the WT1 gene are found in patients with bilateral WT and/or associated genital tract malformations (GU). We have identified 19 hemizygous WT1 gene mutations/deletions in 64 patient samples. The histology of the tumors with mutations was stromal-predominant in 13, triphasic in 3, blastemal-predominant in 1, and unknown in 2 cases. Thirteen of 21 patients with stromal-predominant tumors had WT1 mutations and 10 of these were present in the germ line. Of the patients with germ-line alterations, six had GU and a unilateral tumor, two had a bilateral tumor and normal GU tracts, and two had a unilateral tumor and normal GU. Three mutations were tumor-specific and were found in patients with unilateral tumors without GU. These data demonstrate a correlation of WT1 mutations with stromal-predominant histology, suggesting that a germ-line mutation in WT1 predisposes to the development of tumors with this histology. Twelve mutations are nonsense mutations resulting in truncations at different positions in the WT1 protein and only two are missense mutations. Of the stromal-predominant tumors, 67% showed loss of heterozygosity, and in one tumor a different somatic mutation in addition to the germ-line mutation was identified. These data show that in a large proportion of a histopathologically distinct subset of WTs the classical two-hit inactivation model, with loss of a functional WT1 protein, is the underlying cause of tumor development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108089      PMCID: PMC20552          DOI: 10.1073/pnas.94.8.3972

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  [Preoperative chemotherapy of nephroblastoma. Preliminary results of the SIOP-9/GPO therapy study].

Authors:  R Ludwig; A Weirich; R Pötter; D Harms; D Bürger; J Michaelis; R Erttmann; P Weinel; R J Haas; J Ritter
Journal:  Klin Padiatr       Date:  1992 Jul-Aug       Impact factor: 1.349

2.  RNA polymerase chain reaction detects different levels of four alternatively spliced WT1 transcripts in Wilms' tumors.

Authors:  B Brenner; G Wildhardt; S Schneider; B Royer-Pokora
Journal:  Oncogene       Date:  1992-07       Impact factor: 9.867

3.  Nonlinkage of 16q markers to familial predisposition to Wilms' tumor.

Authors:  V Huff; A E Reeve; M Leppert; L C Strong; E C Douglass; C F Geiser; F P Li; A Meadows; D F Callen; G Lenoir
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

4.  A single base pair polymorphism in the WT1 gene detected by single-strand conformation polymorphism analysis.

Authors:  N Groves; P N Baird; A Hogg; J K Cowell
Journal:  Hum Genet       Date:  1992-12       Impact factor: 4.132

5.  Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.

Authors:  K Pritchard-Jones; S Fleming
Journal:  Oncogene       Date:  1991-12       Impact factor: 9.867

6.  Coordinate expression of Wilms' tumor genes correlates with Wilms' tumor phenotypes.

Authors:  H Yeger; C Cullinane; A Flenniken; S Chilton-MacNeil; C Campbell; A Huang; L Bonetta; M J Coppes; P Thorner; B R Williams
Journal:  Cell Growth Differ       Date:  1992-12

7.  Wilms' tumor-specific methylation pattern in 11p13 detected by PFGE.

Authors:  B Royer-Pokora; S Schneider
Journal:  Genes Chromosomes Cancer       Date:  1992-09       Impact factor: 5.006

Review 8.  TP53 tumor suppressor gene: a model for investigating human mutagenesis.

Authors:  C Caron de Fromentel; T Soussi
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

9.  RNA expression of the WT1 gene in Wilms' tumors in relation to histology.

Authors:  H Miwa; G E Tomlinson; C F Timmons; V Huff; S L Cohn; L C Strong; G F Saunders
Journal:  J Natl Cancer Inst       Date:  1992-02-05       Impact factor: 13.506

10.  Zinc finger point mutations within the WT1 gene in Wilms tumor patients.

Authors:  M H Little; J Prosser; A Condie; P J Smith; V Van Heyningen; N D Hastie
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

View more
  32 in total

Review 1.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

2.  Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.

Authors:  Richard D Williams; Reem Al-Saadi; Tasnim Chagtai; Sergey Popov; Boo Messahel; Neil Sebire; Manfred Gessler; Jenny Wegert; Norbert Graf; Ivo Leuschner; Mike Hubank; Chris Jones; Gordan Vujanic; Kathy Pritchard-Jones
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

Review 3.  Wilms' tumour: a complex enigma to decipher.

Authors:  María José Robles-Frías; Michele Biscuola; María Angeles Castilla; María Angeles López-García; Felicia Sánchez-Gallego; José Palacios
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

4.  Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Authors:  A K Charles; K W Brown; P J Berry
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

5.  Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1.

Authors:  D J Richard; V Schumacher; B Royer-Pokora; S G Roberts
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

6.  Loss of heterozygosity at 11p13 and 11p15 in Wilms tumor: a study of 22 cases from India.

Authors:  Elanthenral Sigamani; Mohammad Nahidul Wari; Venkateswaran K Iyer; Sandeep Agarwala; Arundhati Sharma; Sameer Bakhshi; Amit Dinda
Journal:  Pediatr Surg Int       Date:  2013-01-05       Impact factor: 1.827

7.  Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations.

Authors:  Gil Chernin; Virginia Vega-Warner; Dominik S Schoeb; Saskia F Heeringa; Bugsu Ovunc; Pawaree Saisawat; Roxana Cleper; Fatih Ozaltin; Friedhelm Hildebrandt
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

8.  Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.

Authors:  Maike Busch; Heinrich Schwindt; Artur Brandt; Manfred Beier; Nicole Görldt; Paul Romaniuk; Eneda Toska; Stefan Roberts; Hans-Dieter Royer; Brigitte Royer-Pokora
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

9.  Wilms tumor arising in a child with X-linked nephrogenic diabetes insipidus.

Authors:  Reyhan El-Kares; Pierre-Alain Hueber; Miriam Blumenkrantz; Diana Iglesias; Kim Ma; Nada Jabado; Daniel G Bichet; Paul Goodyer
Journal:  Pediatr Nephrol       Date:  2009-03-18       Impact factor: 3.714

10.  Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.

Authors:  Simone T Sredni; Samantha Gadd; Chiang-Ching Huang; Norman Breslow; Paul Grundy; Daniel M Green; Jeffrey S Dome; Robert C Shamberger; J Bruce Beckwith; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.